These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 35394898)

  • 81. sIPV process development for costs reduction.
    Thomassen YE; Bakker WA
    Vaccine; 2015 Aug; 33(35):4307-12. PubMed ID: 25858858
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Effects of the thermal denaturation of Sabin-derived inactivated polio vaccines on the D-antigenicity and the immunogenicity in rats.
    Murakami K; Fujii Y; Someya Y
    Vaccine; 2020 Apr; 38(17):3295-3299. PubMed ID: 32197923
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Immunogenicity of a combined schedule of trivalent oral and inactivated polio vaccines in South African infants.
    Moonsamy S; Suchard MS; Madhi SA
    Expert Rev Vaccines; 2019 Jul; 18(7):751-754. PubMed ID: 31194605
    [No Abstract]   [Full Text] [Related]  

  • 84. Immunogenicity and safety of a new hexavalent vaccine (DTaP5-IPV-HB-Hib) administered in a mixed primary series schedule with a pentavalent vaccine (DTaP5-IPV-Hib).
    Martinón-Torres F; Boisnard F; Thomas S; Sadorge C; Borrow R;
    Vaccine; 2017 Jun; 35(30):3764-3772. PubMed ID: 28583305
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Antibody response and viral excretion after live polio vaccine or a combined schedule of live and inactivated polio vaccines.
    Ramsay ME; Begg NT; Gandhi J; Brown D
    Pediatr Infect Dis J; 1994 Dec; 13(12):1117-21. PubMed ID: 7892081
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Immunogenicity and safety of the inactivated poliomyelitis vaccine made from Sabin strains in a phase IV clinical trial for the vaccination of a large population.
    Jiang R; Liu X; Sun X; Wang J; Huang Z; Li C; Li Z; Zhou J; Pu Y; Ying Z; Yin Q; Zhao Z; Zhang L; Lei J; Bao W; Jiang Y; Dou Y; Li J; Yang H; Cai W; Deng Y; Che Y; Shi L; Sun M
    Vaccine; 2021 Mar; 39(9):1463-1471. PubMed ID: 33487470
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Comparative evaluation of immunization with live attenuated and inactivated poliovirus vaccines.
    Ogra PL
    Ann N Y Acad Sci; 1995 May; 754():97-107. PubMed ID: 7625685
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Evaluation of vaccine derived poliovirus type 2 outbreak response options: A randomized controlled trial, Karachi, Pakistan.
    Saleem AF; Yousafzai MT; Mach O; Khan A; Quadri F; Weldon WC; Oberste MS; Zaidi SS; Alam MM; Sutter RW; Zaidi AKM
    Vaccine; 2018 Mar; 36(13):1766-1771. PubMed ID: 29477307
    [TBL] [Abstract][Full Text] [Related]  

  • 89. A national reference for inactivated polio vaccine derived from Sabin strains in Japan.
    Shirato H; Someya Y; Ochiai M; Horiuchi Y; Takahashi M; Takeda N; Wakabayashi K; Ouchi Y; Ota Y; Tano Y; Abe S; Yamazaki S; Wakita T;
    Vaccine; 2014 Sep; 32(40):5163-9. PubMed ID: 25090648
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Comparison of the reactogenicity and immunogenicity of a combined diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated polio (DTPa-HBV-IPV) vaccine, mixed with the Haemophilus influenzae type b (Hib) conjugate vaccine and administered as a single injection, with the DTPa-IPV/Hib and hepatitis B vaccines administered in two simultaneous injections to infants at 2, 4 and 6 months of age.
    Arístegui J; Dal-Ré R; Díez-Delgado J; Marés J; Casanovas JM; García-Corbeira P; De Frutos E; Van Esso D; Verdaguer J; De la Flor J; Moraga F; Boceta R; García-Martínez JA
    Vaccine; 2003 Sep; 21(25-26):3593-600. PubMed ID: 12922087
    [TBL] [Abstract][Full Text] [Related]  

  • 91.
    Zhao T; Mo Z; Ying Z; Huang T; Che Y; Li G; Yang X; Sun M; Jiang L; Shi L; Ye H; Zhao Z; Liu X; Li J; Li Y; Li R; Jiang R; Wang J; Fu Y; Ma R; Shi H; Yang H; Li C; Yang J; Li Q
    Ann Transl Med; 2021 Feb; 9(3):253. PubMed ID: 33708880
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Immune Persistence following Primary Immunization and the Immunogenicity and Safety of a Booster Dose of a Multidose Sabin Strain-Based Inactivated Polio Vaccine in Infants Aged 18 Months.
    Feng G; Shao M; Wang J; Huang L; Tan J; Jiang Z; You W; Li Y; Yang Y; Li J; Wang Y
    Vaccines (Basel); 2024 Jan; 12(2):. PubMed ID: 38400106
    [TBL] [Abstract][Full Text] [Related]  

  • 93. The novel adjuvant dmLT promotes dose sparing, mucosal immunity and longevity of antibody responses to the inactivated polio vaccine in a murine model.
    Norton EB; Bauer DL; Weldon WC; Oberste MS; Lawson LB; Clements JD
    Vaccine; 2015 Apr; 33(16):1909-15. PubMed ID: 25765967
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Immune response of infants to fractional doses of intradermally administered inactivated poliovirus vaccine.
    Nirmal S; Cherian T; Samuel BU; Rajasingh J; Raghupathy P; John TJ
    Vaccine; 1998; 16(9-10):928-31. PubMed ID: 9682339
    [TBL] [Abstract][Full Text] [Related]  

  • 95. The progress of postapproval clinical studies on Sabin IPV.
    Shi L; Sun M
    Hum Vaccin Immunother; 2022 Dec; 18(1):1-4. PubMed ID: 34213408
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Oral and inactivated poliovirus vaccines in the newborn: a review.
    Mateen FJ; Shinohara RT; Sutter RW
    Vaccine; 2013 May; 31(21):2517-24. PubMed ID: 22728224
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Results of a clinical study of polio vaccine: the Buffalo experience.
    Faden H
    Pediatr Infect Dis J; 1991 Dec; 10(12):973-5. PubMed ID: 1766725
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Priming after a fractional dose of inactivated poliovirus vaccine.
    Resik S; Tejeda A; Sutter RW; Diaz M; Sarmiento L; Alemañi N; Garcia G; Fonseca M; Hung LH; Kahn AL; Burton A; Landaverde JM; Aylward RB
    N Engl J Med; 2013 Jan; 368(5):416-24. PubMed ID: 23363495
    [TBL] [Abstract][Full Text] [Related]  

  • 99. [Immunogenicity of sabin inactivated poliovirus vaccine induced by diphtheria-tetanus-acellular pertussis and Sabin inactivated poliovirus combined vaccine].
    Ma Y; Qin M; Hu HQ; Ji G; Feng L; Gao N; Gu J; Xie BF; He JH; Sun MB
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2011 Jun; 25(3):197-200. PubMed ID: 21977591
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Lower immunity to poliomyelitis viruses in Australian young adults not eligible for inactivated polio vaccine.
    Hendry AJ; Beard FH; Dey A; Quinn H; Hueston L; Dwyer DE; McIntyre PB
    Vaccine; 2020 Mar; 38(11):2572-2577. PubMed ID: 32037225
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.